The nation of Zimbabwe has turned down a major US healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years due to Washington's demand for confidential information.
This rejection came to light following a internal memorandum from December was disclosed, indicating that President Emmerson Mnangagwa believed the arrangement was "skewed".
An official spokesman later explained that the United States was demanding access to biological samples for research and profit but refused to guarantee the benefits from future medical innovations.
"We must now begin the challenging and unfortunate process of winding down our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had donated over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for further talks to secure a agreement suitable to both sides so the country's vital HIV programme can continue.
Wider Context
Zimbabwe's decision follows a comparable situation in neighbouring Kenya, where a high court suspended a related deal with the US following concerns were raised about the safety of citizens' health data.
After returning to office recently, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had overseen assistance for the US government, but Trump argued its spending was "inefficient" and his government was seeking direct bilateral deals to boost openness and accountability.
Based on reports, 16 nations in Africa have to date agreed to similar agreements, representing more than $18.3bn in committed funds.
Specifics of the Declined Deal
The funds for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this collaboration would have delivered extraordinary advantages for the people of Zimbabwe, especially the 1.2 million men, women and children currently on HIV treatment through American-funded initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to provide its genetic material and health information indefinitely, without any corresponding assurance of access to any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," his statement read.
"Effectively, our nation would supply the raw materials for medical research with no certainty that the resulting innovations would be available to our citizens should a future health crisis arise."
Sovereignty and Global Health
Mangwana further said that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were undermining structures previously set up through the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework designed to manage future pandemics.
"This framework is intended to ensure that when a country contributes its data, the resulting advantages – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the resources to develop them."
Zimbabwe's reservations over the US deal "must not be interpreted as opposition to America," he added.
"We encourage ongoing dialogue with our American counterparts on how subsequent collaboration might be designed in a way that honours the independence and interests of each country."
Medical Community Reaction
A leading public health body expressed it understood the official position, but recommended that talks must proceed since a large portion of the country's HIV programmes were funded by external financing.
"Where technical issues arise, including those relating to information security or agreement terms, these can often be resolved via detailed discussion and mutually agreed protections," the group added.
The situation emphasises the complex debate between accepting much-needed international aid and protecting a country's data in an ever more data-driven world.